Pharmaceutical Manufacturing
-
-
Shanghai Henlius Biotech, Inc.
Han Bei Tai
Common Name：Bevacizumab Injection
HANBEITAI (bevacizumab injection) was approved by the NMPA in November 2021. It is indicated for metastatic colorectal cancer (mCRC), advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, cervical cancer, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. It is the only bevacizumab with metastatic colorectal cancer Phase III clinical data in China and proposed to be combined with HANSIZHUANG (PD-1) for immuno-oncology combination therapies to treat various tumors.
-
-
Shanghai Henlius Biotech, Inc.
Han Si Zhuang
Common Name：Serplulimab Injection
HANSIZHUANG (serplulimab injection, anti-PD-1 mAb), company’s first self-developed innovative monoclonal antibody, was launched in March 2022. It has been approved by the NMPA for the treatment of Microsatellite Instability-High (MSI-H) solid tumors, squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. Henlius actively promotes HANSIZHUANG in conjunction with in-house products of the company and innovative therapies, and has initiated many clinical trials on immuno-oncology combination therapies worldwide, covering a wide range of indications, such as lung cancer, esophageal carcinoma, head and neck squamous cell carcinoma and gastric cancer, etc. Its NDA for the treatment esophageal squamous cell carcinoma (ESCC) is under review.
-
-
osun Kite Biotechnology Co., Ltd.
Yescarta®
Common Name：Axicabtagene Ciloleucel Injection
In June 2021, NMPA approved Axicabtagene Ciloleucel Injection from Fosun Kite, the first CAR-T cell product for marketing in China for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
-
-
Shanghai Henlius Biotech, Inc.
Han Li Kang
Common Name：Rituximab Injection
HANLIKANG (rituximab injection) is the company's first proprietary product. It is the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guideline for the Development and Evaluation of Biosimilars (Tentative) issued in 2015. As of now, HANLIKANG has been approved by the NMPA for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis for which the originator rituximab has not been approved in China, benefiting a wider patient population with differentiated strategies.
-
-
Shanghai Henlius Biotech, Inc.
Han Qu You
Common Name：Trastuzumab
HANQUYOU (trastuzumab, Zercepac® in Europe，Trade names in Australia: Tuzucip® and Trastucip®) was successfully launched in China and Europe, becoming the first Chinese mAb biosimilar entering both the EU and China market. It is indicated for the treatment of HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer, which corresponds to all the approved indications of the trastuzumab originator. HANQUYOU is certificated by China and the EU GMP. It brings more treatment options to patients with HER2 positive breast and gastric cancer worldwide.
-
-
Fosun Pharma
Doptelet
Common Name：Avatrombopag Maleate Tablets
It is the first drug approved for the treatment of thrombocytopenia associated with chronic liver diseases (CLD) in China that has been included in the National Reimbursement Drug List (NRDL) to benefit more patients! In addition, it's phase III clinical trial for the treatment of chronic immune thrombocytopenia (ITP) is ongoing.
-
-
YaoPharma Co., Ltd.
Di Kai Mei
Common Name：Sorafenib Tosylate Tablets
This is category B product covered in National Reimbursement Drug List; approved by national consistency evaluation and covered in National Centralized Drug Procurement List; recommended by Chinese and global authoritative guidelines to be as first-line therapy drug for advanced hepatocellular carcinoma. Dual anti-tumor mechanism: Inhibition of tumor cell proliferation and tumor neovascularization.
-
-
Shanghai Henlius Biotech, Inc.
Han Da Yuan
Common Name：Adalimumab Injection
The Company's first product indicated for the treatment of autoimmune diseases. HANDAYUAN (adalimumab injection) was approved by the NMPA in December 2020. It is indicated for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis and uveitis. It is the first China-developed adalimumab biosimilar that is manufactured in a China and Europe GMP certificated manufacturing site, as well as the only adalimumab biosimilar evaluated in a Phase 3 clinical study among Chinese patients with plaque psoriasis.
-
-
Hebei Wanbang Folon Pharmaceutical Co., Ltd.
Ke Sheng
Common Name：Xihuang Capsules
Resolve toxin and dissipate binds, decrease swelling and relieve pain. For the syndrome of toxicity and acute blood stasis, superficial infection, dorsal furuncle swelling, multiple abscess, adenolymphitis, cold abscess
-
-
Shanghai Zhaohui Pharmaceutical Co., Ltd.
ZhaoHuiXian
Common Name：Bicalutamide Tablets
Indicated for the treatment of advanced prostate cancer in combination with luteinising hormone- releasing hormone (LHRH) analogues or surgical orchiectomy.
-
-
YaoPharma Co., Ltd.
Kai Lai Zhi
Common Name：Epinastine Hydrochloride Capsules
This is the first generic drug in China with exclusive dosage form; with triple anti-allergic mechanism to effectively treat various allergic diseases; recommended by multiple guidelines and consensuses; first-line therapy drug for allergic diseases such as urticaria, dermatitis, eczema and allergic rhinitis.
-
-
Shanghai Chemo Wanbang Biopharma Co., Ltd.
YiLuoZe
Common Name：Pemetrexed Disodium for Injection
Non-small cell lung cancer (NSCLC): single is for the treatment of patients with locally advanced or metastatic NSCLC who have progressed after previous first-line chemotherapy. This product is not recommended for use in patients with histologically dominant squamous cell carcinoma. Malignant pleural mesothelioma: this product is used in combination with cisplatin to treat inoperable malignant pleural mesothelioma.